Nina Bhardwaj, MD, PhD
Director of Immunotherapy; Medical Director, Vaccine and Cell Therapy Laboratory; Co-Director, Cancer Immunology Program
Icahn School of Medicine at Mount Sinai
Nina Bhardwaj MD, PhD, is Professor of Medicine (Hematology and Medical Oncology) and Urology. She is the Director of Immunotherapy, Medical Director of the Vaccine and Cell Therapy Laboratory, and Co-Director of the Cancer Immunology Program at The Tisch Cancer Institute. She is a faculty member of the Icahn Genomics Institute. Dr. Bhardwaj holds the Ward Coleman Chair in Cancer Research. Dr. Bhardwaj has made seminal contributions to human dendritic cell biology, specifically with respect to their isolation, subset discovery, immunobiology, antigen presenting function, and use of vaccine adjuvants in humans. She developed Toll Like Receptor agonist- and dendritic cell-based vaccines for the treatment of both cancer and infection in several investigator-initiated studies and has pioneered neoantigen vaccine studies at The Tisch Cancer Institute. Dr. Bhardwaj translates basic science advancements into clinically relevant patient trials. Dr. Bhardwaj was named one of the Scientific American's Top 50 Researchers, receiving the Award for Medical Research in 2004. She received the Fred W. Alt Award for new discoveries in Immunology in 2015 from the Cancer Research Institute. Dr. Bhardwaj was awarded the Berson-Yallow Society Lectureship in 2019 and received the Jacobi Medallion Award in 2020, both from the Icahn School of Medicine at Mount Sinai. She received the 2022 Lifetime Achievement in Cancer Research award from the American Association of Indian Scientists in Cancer Research (AAISCR) for her significant contributions to cancer research. Dr. Bhardwaj just received the European Society for Medical Oncology's (ESMO) Award for Immuno-Oncology 2022. The ESMO award, established in 2017 in memory of Professor Georges Mathé, recognizes outstanding contributions to the field of immuno-oncology. Dr. Bhardwaj is a senior editor for Cancer Immunology Research and Frontiers in Immunology. She has served on numerous National Institutes of Health Study Sections and advisory councils and as Chair of the Cancer Immunology Steering Committee of the American Association for Cancer Research, where she also serves on the Board of Directors. Dr. Bhardwaj has successfully secured multiple federal and foundation grants and has authored more than 250 publications.
Nina Bhardwaj, MD, PhD